Sarac, F.Basoglu, O. K.Gunduz, C.Bayrak, H.Avci, C. BirayAkcicek, F.2019-10-272019-10-2720110391-4097https://doi.org/10.3275/7287https://hdl.handle.net/11454/46268Objective: The aims of this study were to compare the tumor necrosis factor (TNF)-alpha and osteopontin levels, to identify the relationship between insulin resistance (IR) and osteopontin levels in obese patients with and without obstructive sleep apnea syndrome (OSAS). Method: The study population included 62 obese patients (35 males, 27 females) with OSAS and was compared with 26 obese patients (16 males, 10 females) without OSAS as a control group. Polysomnographic evaluation, spirometric tests and arterial blood gas sampling were performed on the obese patients with OSAS. Plasma levels of INF-alpha and osteopontin were measured by enzyme-linked immunosorbent assays during the process. IR was estimated using the homeostasis model assessment (HOMA). Results: Mean plasma levels of fasting glucose, insulin, HOMA, liver function test, hematocrit, leukocyte, TSH, free T(4), fibrinogen, INF-alpha, and osteopontin were similar in the 2 groups. In patients with OSAS, mean osteopontin levels were positively correlated with mean fasting insulin levels (r=0.306, p=0.01), HOMA (r=0.299, p=0.01), apnea-hypopnea index (r=0.377, p=0.03) and Epworth Sleepiness Scale (r=0.299, p=0.01). However, mean INF-alpha levels were negatively correlated with Epworth Sleepiness Scale (r=-0.298, p=0.01) in the patients with OSAS. Conclusions: It was observed that INF-alpha and osteopontin levels showed no difference between obese patients with and without OSAS. However, osteopontin levels increased with fasting insulin, IR, OSAS severity, and daytime sleepiness. (J. Endocrinol. Invest. 34: 528-533, 2011) (C) 2011, Editrice Kurtisen10.3275/7287info:eu-repo/semantics/closedAccessInsulin resistanceobesityobstructive sleep apnea syndromeosteopontinTNF-alphaArticle347528533WOS:00029556260000820935448Q4